Integra LifeSciences Holdings Corporation’s $575 Million Convertible Senior Notes Offering


Davis Polk advised the joint book-running managers and representatives of the initial purchasers in connection with the offering.

Integra LifeSciences Holdings Corporation completed the offering of $575 million aggregate principal amount of its 0.50% convertible senior notes due 2025 (which included the full exercise of the initial purchasers’ option to purchase additional notes).

BofA Securities, Inc., Morgan Stanley & Co. LLC and SunTrust Robinson Humphrey, Inc. acted as initial purchasers for the offering.

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery.

The Davis Polk corporate team included partner Yasin Keshvargar (Picture) and associates Ida Araya-Brumskine and Roman Shapurko. The equity derivatives team included partner Ray Ibrahim and associates Joseph Luizzi and Annie Li. Partner Lucy W. Farr and associate Eitan Ulmer provided tax advice. Counsel Bonnie Chen and associate Yifu Chen provided intellectual property advice.

Involved fees earner: Ida Araya-Brumskine – Davis Polk & Wardwell; Bonnie Chen – Davis Polk & Wardwell; Yifu Chen – Davis Polk & Wardwell; Lucy Farr – Davis Polk & Wardwell; Ray Ibrahim – Davis Polk & Wardwell; Yasin Keshvargar – Davis Polk & Wardwell; Annie Li – Davis Polk & Wardwell; Joseph Luizzi – Davis Polk & Wardwell; Roman Shapurko – Davis Polk & Wardwell; Eitan Ulmer – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Bank of America Securities; Morgan Stanley; SunTrust Robinson Humphrey, Inc.;

Author: Ambrogio Visconti